Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2006

View Archived Issues

Long-term hepatitis C virus suppression seen with valopicitabine and peg-interferon

Bavituximab safe in phase I hepatitis C study

Phase II study shows eltrombopag efficacy in HCV-associated thrombocytopenia

Studies detail long-term hepatitis B viral suppression with telbivudine

Interferon alfacon-1/ribavirin shows promise in HCV peg-interferon nonresponders

Idenix to enhance hepatitis C pipeline through Metabasis collaboration

Daytrana shown to give individualized ADHD symptom management

Phase III study of naproxcinod in osteoarthritis meets primary endpoints

Intercell and MSD to develop prophylactic vaccine against Group A Streptococcus

Action Pharma's pipeline development supported by new venture capital

RTA-744 awarded orphan drug status for malignant gliomas

Shionogi discontinues development of S-5751

Strattera improves ADHD symptoms in subjects with reading disorder

R-7128 begins phase I study for HCV

Argos awarded NIH contract to further develop HIV immunotherapy candidates

New phase I study to investigate WT1 peptide therapeutic vaccine INNO-305

Chugai reviews highlights of third quarter

Preclinical studies of FTI tipifarnib encourage clinical investigation in HGPS

Fluphenazine decanoate to be evaluated for the management of psoriasis in phase II clinical trial

Nicotinamide protects against axonal degeneration in MS model / News in Context

Emerging natural products for the treatment of neurological disorders: Part I

New treatments for cancer covered in recent patent literature

Recent Pfizer patent describes new dopamine D2 receptor ligands for schizophrenia

Novel alpha1A/1D-adrenoceptor antagonists reported by Janssen

Novel agents for dental caries claimed by Queen Mary, University of London

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...